Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease
Authors' conclusion
The impact of T2D on adverse outcomes is significantly mediated through chronic inflammation and immune dysregulation, estimated using suPAR levels. Whether novel therapies for reducing suPAR levels will impact CHD risk in T2D warrants further investigation.
Study context
- Population
- Patients with and without coronary heart disease (CHD) enrolled in the Emory Cardiovascular Biobank; mean age 64 years, 36% women, 31.8% with T2D
- Participants
- 4,324 patients
- Exposure
- T2D vs no T2D
- Outcome
- Cardiovascular death
- Follow-up
- Median 6.9 years
Methodological detailscausal mediation analysis, Fine and Gray or Cox proportional hazards models, adjusted for demographic, clinical and treatment variables
- Causal mediation analysis
- Fine and Gray or Cox proportional hazards models
- Adjusted for demographic, clinical and treatment variables
Main finding
As reported in the abstract
median 6.9 years
T2D vs No T2DEstimate (95% CI)P value
Cardiovascular death
adjusted HR 1.38(1.16–1.63)
P < 0.001Greatly attenuated after adjustment for suPAR, but not hs-CRP
HR after adjustment for suPAR 1.18(0.99–1.40)
P = 0.1Observational data: associations, not effects.
Further findings
suPAR levels
Incident MI and cardiovascular death composite; all-cause death
- Similar findings were observed for the other outcomes
Original publication
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Mediates the Impact of Diabetes on Adverse Outcomes in Coronary Artery Disease. Diabetes Care. Published 14 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →